All In Biotech

Drug Trial Radar · NCT06735391

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

A Phase 3 Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 516 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

516

Planned (sponsor's estimate)

Start

Oct 23, 2024

Primary completion

Sep 30, 2026

Study completion May 30, 2029

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Dec 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.

Conditions

  • Locally Advanced or Metastatic Non-squamous NSCLC
  • Harboring EGFR Sensitive Mutations NSCLC
  • Previously Untreated Systematically NSCLC

Interventions

  • JMT101Drug

    JMT101 is a recombinant humanized anti-EGFR monoclonal antibody.

  • OsimertinibDrug

    EGFR TKI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by the independent review committee (IRC) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Up to approximately 44 months after the first participant is enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat sen University Cancer Prevention and Treatment Center

    Guangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.